Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2024

Genmab — Juli 2024

Planlagt Fastgjort Låst Flyttet Genmab
568 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • V Offline
    V Offline
    Vitus
    wrote on sidst redigeret af
    #398

    Det er super …

    1 Reply Last reply
    0
    • M Offline
      M Offline
      MarsFars
      wrote on sidst redigeret af
      #399

      Hvordan er det at krydse 1900 ovenfra her en time senere? Betyder det egentlig noget?

      1 Reply Last reply
      0
      • M Offline
        M Offline
        Marlin
        wrote on sidst redigeret af
        #400

        Novo splittede 1:5 i 2014 og igen 1:2 i 2023 og har givet udbytte og foretaget aktietilbagekøb siden 2011.

        1 Reply Last reply
        0
        • H Offline
          H Offline
          Hugininvest
          wrote on sidst redigeret af
          #401

          Der er ingen hage ved 1900, bortset fra det runde tal.

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #402

            another small epco trial - Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab https://www.clinicaltrials.gov/study/NCT06447376

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #403

              Another Epkinly lymphoma combo goes pivotal https://www.oncologypipeline.com/apexonco/another-epkinly-lymphoma-combo-goes-pivotal

              1 Reply Last reply
              0
              • M Offline
                M Offline
                MarsFars
                wrote on sidst redigeret af
                #404

                Dejligt at krydse 1881,50 kr nedefra 🙂

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #405

                  Tisotumab vedotin effective in recurrent cervical cancer - article in Nature, can't read it all,
                  but anyway.. https://www.nature.com/articles/s41571-024-00929-4

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #406

                    ESMO 2024 preview – conjugates in the spotlight https://www.oncologypipeline.com/apexonco/node/734 rinatabart

                    1 Reply Last reply
                    0
                    • H Offline
                      H Offline
                      Hen
                      wrote on sidst redigeret af
                      #407

                      Medicinalselskabet Genmab har fået skruet på kursmålet af amerikanske Goldman Sachs. Investeringsbanken øger målet til 2378 kr. fra 2242 kr., mens anbefalingen fastholdes som "neutral". Marketwire.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #408

                        Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL https://www.youtube.com/watch?v=SQgjUgIJU4E

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #409

                          Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer https://www.targetedonc.com/view/tisotumab-vedotin-continues-to-show-survival-benefits-in-recurrent-cervical-cancer

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #410

                            Thanks E L.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #411

                              from the Morningstart report on Novartis: several other drugs continue to post rapid gains. In particular, multiple
                              sclerosis drug Kesimpta (up 65%) holds the potential to exceed management's peak annual sales
                              guidance of $4 billion based on leading efficacy and convenient dosing

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #412

                                Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I https://www.geneonline.com/topo-1-and-frα-key-focus-areas-and-major-collaborations-in-adc-research-part-i/

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #413

                                  Genmab i teknisk udbrud op gennem 50 dages MA, plus 12 % på tre uger https://ugebrev.dk/flashnews/genmab-i-teknisk-udbrud-op-gennem-50-dages-ma-plus-12-paa-tre-uger/

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #414

                                    MA200 ligger omkring 2024 kr jf Yahoo. Det ville være dejligt med en konsolidering over dette niveau 😉 Men selvfølgelig tilfreds MA50 til en start.

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Raun
                                      wrote on sidst redigeret af
                                      #415

                                      Et spørgsmål til teknikerne..... Hvornår gør et gap luk sig gældende?.... Tænker at nu har vi set Genmab forhåbentlig have lavet en vending/bund i omkring kurs 1700.... Nu da aktien jo egentlig ikke har dannet en bund i dette niveau, siger teknikken så at vi skal have lukket det gap, førend en eventuel optur kan fortsætte?

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #416

                                        Gap er spring i kursniveauerne fra dag til dag. Men jo nogen gange er der dobbeltbund eller -top, hvilket er noget andet.

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #417

                                          Men der er sikkert en der har syr på det 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper